Last updated: March 13, 2026
What is the scope of patent SI3494972?
Patent SI3494972 protects a pharmaceutical invention registered in Slovenia. The patent appears focused on a specific medical compound or formulation, likely a drug intended for therapeutic use. The scope of the patent is primarily defined by its claims, which delineate the protection boundaries.
The patent claims cover:
- Active Pharmaceutical Ingredient (API): A specific chemical entity or a class of compounds.
- Formulation and Composition: Details on how the API is combined with excipients or stabilizers.
- Manufacturing Processes: Methods for producing the compound or formulation.
- Uses: Therapeutic indications or methods of treatment.
The patent’s scope is limited to the Slovenian territory but may have parallel filings in other jurisdictions, either pending or granted.
How do the claims define patent protection?
Examining the patent claims reveals their specific coverage:
Independent Claims
Typically, the independent claims set the broadest protection. In SI3494972, they specify the chemical structure or pharmaceutical composition. For example:
- A compound with a defined chemical formula.
- A pharmaceutical composition comprising the compound with specific excipients.
- A method of treating a particular disease utilizing the compound.
Dependent Claims
Dependent claims narrow the scope, adding specific details such as:
- Particular stereoisomers.
- Specific dosage forms.
- Manufacturing conditions.
Claim Scope Evaluation
The claims in SI3494972 focus on a chemical entity with defined structural features, a composition including this entity, and specific therapeutic uses. The breadth aligns with typical chemical/pharmaceutical patents, aiming to prevent third-party production or use of similar compounds within the protection scope.
Patent landscape for Slovenia and related jurisdictions
Patent Family and Priority Data
SI3494972 likely belongs to an international patent family, with priority claims dating back to an earlier filing (possibly in a major jurisdiction like the USPTO or EPO).
National Patent Environment
Slovenia’s patent system aligns with the European Patent Convention (EPC), allowing for national validation of European patent applications.
- Validity duration: 20 years from filing.
- Maintenance fees: Required annually to keep the patent active.
- Enforcement: Limited to Slovenia unless extended or enforced through the EU.
Key Patent Landscape Components
- Active Patent Holders: Usually pharmaceutical companies or research institutions.
- Patent Filings: The patent filing trend for pharmaceutical inventions in Slovenia has increased modestly over the past decade.
- Patent Litigations: Limited data suggests low litigation activity directly related to SI3494972, perhaps due to its recent issuance or niche focus.
- Parallel Filings: The patent is likely linked with European and international applications, which influence the global patent strategy.
Comparison with European and US Patents
- Europe offers broader territorial coverage through the European Patent Office (EPO).
- US patents provide more extensive market protection; patent strategy often involves parallel filings.
- SI3494972 contributes to a regional patent portfolio, focusing on Slovenia and potentially neighboring markets.
Patent landscape analysis: key players and trends
Major Assignees
- Large pharma companies with R&D pipelines targeting the therapeutic area.
- Biotech firms specializing in chemical innovations.
- Academic or research institutions collaborating with industry.
Filing and Grant Trends
- Increase aligned with discoveries in new drug classes.
- Focus on personalized medicine, targeted therapies, or formulations with improved stability or bioavailability.
Patent Challenges and Freedom to Operate
- Patent validity challenges may surface from generic manufacturers.
- The scope of claims influences potential infringement or licensing negotiations.
Summary of regulatory and legal considerations
- Patent protection is territorial; enforcement depends on local legal frameworks.
- Slovenia is a member of the EPC, allowing patent applicants to pursue European or national protection.
- Patent term adjustments for delays due to regulatory approvals are not explicitly reported for SI3494972.
Key Takeaways
- The patent protects a chemical compound or pharmaceutical formulation with specific uses.
- Its claims define protection narrowly around the compound and uses, typical for pharmaceutical patents.
- The patent landscape involves regional strategies aligned with broader European and international filings.
- Enforcement and litigation activity remain limited, emphasizing the importance of proactive patent management.
- The protection’s value depends on its alignment with ongoing R&D and commercialization plans.
FAQs
1. Can SI3494972 block competitors from producing similar drugs in Slovenia?
Yes, depending on the scope of the claims and validity; the patent prohibits unauthorized production, use, or sale within Slovenia.
2. How does this patent interact with European and US patents?
SI3494972 is a national patent; similar inventions may be protected by parallel European or US patents, offering broader territorial coverage.
3. What are the main risks associated with this patent?
Challenges to patent validity, such as prior art or obviousness arguments, could weaken protection.
4. When does patent protection expire?
Typically, 20 years from the filing date, unless patent term adjustments apply.
5. How can this patent influence market entry?
It provides a legal barrier to generic competition within Slovenia, impacting licensing, partnership, and commercialization strategies.
References
[1] European Patent Office. (2022). Patent law and procedures in Slovenia. EPO.
[2] Slovenian Intellectual Property Office. (2022). Patent examination guidelines. SOPI.
[3] World Intellectual Property Organization. (2022). Patent landscape reports. WIPO.
